Key result
Transcatheter mitral valve-in-valve procedures demonstrated a higher technical success rate compared to valve-in-ring procedures.
Why the study?
Midterm survival rates have been reported for transcatheter mitral valve implantation, but little is known about contemporary morbimortality endpoints.
Does transcatheter mitral valve implantation (valve-in-valve or valve-in-ring) provide safe and effective midterm outcomes in patients with failed surgical annuloplasty rings or deteriorated bioprostheses?
Observational (n=102)
Yes
Does transcatheter mitral valve implantation (valve-in-valve or valve-in-ring) provide safe and effective midterm outcomes in patients with failed surgical annuloplasty rings or deteriorated bioprostheses?
Transcatheter mitral valve-in-valve procedures are safe and effective, whereas valve-in-ring procedures carry a higher risk of procedural complications, with paravalvular leak driving worse midterm outcomes.
Answers are grounded in this paper and cite their sources.
Valve-in-ring mitral procedures may warrant procedural caution versus valve-in-valve; leaves open need for randomized confirmation of midterm outcomes.
OBJECTIVES: Report contemporary outcomes in patients included in the Mitragister registry and treated with transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis. BACKGROUND: Midterm survival rates have been reported, but little is known about contemporary morbimortality endpoints. METHODS: The primary safety outcome was the technical success rate. The primary efficacy composite endpoint was a composite of cardiovascular mortality and heart failure hospitalizations. RESULTS: From 2016 to 2021, 102 patients (median age: 81 [74;84] years, 61% female, Euroscore II 11.0% [7.8;16.0]) undergoing valve-in-valve (ViV; n = 89) or valve-in-ring (ViR; n = 13) procedures were consecutively included. At baseline, ViR group patients had worse left ventricular ejection fraction (50% vs. 60%; p = 0.004) and more frequently severe regurgitation (46% vs. 15%; p = 0.014). The primary safety outcome was 95%: 77% and 98% in the ViR and ViV populations, respectively, (p = 0.014). At intermediate follow-up (6-12 months) clinical improvement was notable, 88% of the patients were in NYHA class ≤ II (vs. 25% at baseline; p < 0.001). At a mean follow-up of 17.1 ± 11.0 months, the primary efficacy composite reached 27%. By multivariate analysis, paravalvular leak (PVL) was the only independent predictor (hazard ratio: 2.39, 95% confidence interval: 1.08-5.29; p = 0.031) while ViR was not found statistically associated (p = 0.456). CONCLUSIONS: This study confirms the safety and efficacy of the mitral ViV procedure. ViR patients appear at higher risk of procedural complications. The presence of PVL could be associated with markedly worse midterm prognosis. Whatever the intervention, procedural strategies to reduce PVL incidence remain to be assessed to prevent latter adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Ruz et al. (2022) conducted an observational in Failed surgical annuloplasty rings or deteriorated bioprosthesis (n=102). Valve-in-valve (ViV) procedure vs. Valve-in-ring (ViR) procedure was evaluated on Technical success rate (p=0.014). Transcatheter mitral valve-in-valve procedures demonstrated a higher technical success rate compared to valve-in-ring procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: